Critically, these data demonstrate the potent effect of BTK-inhibition in B-CLL and, more importantly, provide evidence that ibrutinib is an effective treatment for aggressive forms of B-CLL with TP53 mutation and potentially chemo-resistant refractory disease. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.